MarketCap
Facebook
X
Telegram
Exicure Market Cap | XCUR
As of November 08, 2026 Exicure has a market cap of $ 5.73 M
Capitalization is the market value of a company whose shares are traded on the stock exchange. It is calculated by multiplying the market price of a share by the total number of the company's shares. Capitalization indicates volatility, risk, and growth potential. This metric is often used for a quick assessment of a company’s investment profile.[1]
Capitalization is an important indicator for investors and analysts, as it helps determine the size and significance of a company in the stock market. Companies with large capitalization are considered more stable and reliable, as they have more resources and financial power to grow and survive in the market.
This metric can be divided into several categories: small (from 300 million to 2 billion dollars), medium (from 2 to 10 billion dollars), and large (over 10 billion dollars). Companies with different levels of capitalization have their own characteristics and risks, so investors usually take this indicator into account when making investment decisions.
Capitalization can also change over time depending on the share price and the number of shares in circulation. Therefore, it is a dynamic indicator that requires constant monitoring and analysis to make well-informed investment decisions.
Annual Market Cap Exicure
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 29 M | 9.42 M | 753 K | 4.39 M | 588 K | 186 M | 218 M | 122 M | - | - | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 218 M | 588 K | 71.3 M |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.
Market Cap of other stocks in the Biotechnology industry
| Issuer | Market Cap | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Galmed Pharmaceuticals Ltd.
GLMD
|
3.19 M | $ 4.63 | 21.05 % | $ 20 M |  Israel |
 |
Fennec Pharmaceuticals
FENC
|
169 M | $ 9.79 | 4.26 % | $ 280 M |  USA |
 |
Kiromic BioPharma
KRBP
|
4.83 M | - | 6.61 % | $ 3.08 M | USA |
 |
CNS Pharmaceuticals
CNSP
|
1.06 M | $ 3.92 | -2.24 % | $ 1.74 M | USA |
 |
Calithera Biosciences
CALA
|
49.1 M | - | -10.95 % | $ 876 K | USA |
 |
United Therapeutics Corporation
UTHR
|
23.6 B | $ 562.14 | -0.63 % | $ 24.9 B | USA |
 |
Vericel Corporation
VCEL
|
1.88 B | $ 54.56 | 5.36 % | $ 2.75 B | USA |
 |
Veracyte
VCYT
|
3.04 B | $ 24.1 | 0.42 % | $ 1.89 B | USA |
 |
Applied Molecular Transport
AMTI
|
22.1 M | - | - | $ 10.1 M | USA |
 |
Fulcrum Therapeutics
FULC
|
539 M | $ 3.72 | 0.95 % | $ 236 M | USA |
 |
Molecular Templates
MTEM
|
10.1 M | - | -23.43 % | $ 495 K | USA |
 |
Vanda Pharmaceuticals
VNDA
|
358 M | $ 3.82 | 6.27 % | $ 225 M | USA |
 |
Verrica Pharmaceuticals
VRCA
|
66.7 M | $ 3.22 | 4.21 % | $ 34.3 M | USA |
 |
Viridian Therapeutics
VRDN
|
2.99 B | $ 28.47 | -0.28 % | $ 2.9 B | USA |
 |
BioXcel Therapeutics
BTAI
|
15.4 M | $ 0.07 | 9.81 % | $ 855 K | USA |
 |
VistaGen Therapeutics
VTGN
|
21.7 M | $ 0.17 | 3.45 % | $ 6.47 M | USA |
 |
Voyager Therapeutics
VYGR
|
241 M | $ 1.86 | 8.14 % | $ 109 M | USA |
 |
CohBar
CWBR
|
5.31 M | - | -15.44 % | $ 2.2 M | USA |
 |
NeuBase Therapeutics
NBSE
|
6.27 M | - | -1.56 % | $ 12.3 M | USA |
 |
Gossamer Bio
GOSS
|
107 M | $ 9.77 | 3.72 % | $ 2.23 B | USA |
 |
Deciphera Pharmaceuticals
DCPH
|
1.2 B | - | - | $ 2.18 B | USA |
 |
GeoVax Labs
GOVX
|
1.23 M | $ 0.16 | -5.0 % | $ 153 K | USA |
 |
Arena Pharmaceuticals
ARNA
|
5.65 B | - | -6.81 % | $ 3.04 B | USA |
 |
Scopus BioPharma
SCPS
|
3.8 M | - | -48.37 % | $ 3.71 M | USA |
 |
Annovis Bio
ANVS
|
51.8 M | $ 0.82 | 23.72 % | $ 16.9 M | USA |
 |
scPharmaceuticals
SCPH
|
210 M | - | - | $ 218 M | USA |
 |
Xeris Pharmaceuticals
XERS
|
967 M | $ 15.08 | 15.29 % | $ 2.42 B | USA |
 |
X4 Pharmaceuticals
XFOR
|
179 M | $ 3.15 | 2.61 % | $ 133 M | USA |
 |
Entasis Therapeutics Holdings
ETTX
|
73.7 M | - | - | $ 105 M | USA |
 |
Athersys
ATHX
|
8.07 M | - | 3.77 % | $ 22.4 M | USA |
 |
Zai Lab Limited
ZLAB
|
21.6 B | $ 25.49 | 12.77 % | $ 27.9 B |  China |
 |
Zentalis Pharmaceuticals
ZNTL
|
192 M | $ 1.71 | 2.05 % | $ 123 M | USA |
 |
Zoetis
ZTS
|
56.1 B | $ 79.51 | -3.21 % | $ 35.3 B | USA |
 |
Global Blood Therapeutics
GBT
|
1.82 B | - | - | $ 4.62 B | USA |
 |
Inozyme Pharma
INZY
|
297 M | - | - | $ 207 M | USA |
 |
Idera Pharmaceuticals
IDRA
|
1.4 M | - | -23.04 % | $ 26.6 M | USA |
 |
NanoString Technologies
NSTG
|
459 M | - | -37.43 % | $ 5.1 M | USA |
 |
Humanigen
HGEN
|
12.5 M | - | -81.12 % | $ 4.28 M | USA |
 |
Sorrento Therapeutics
SRNE
|
746 M | - | -29.58 % | $ 126 M | USA |
 |
Surface Oncology
SURF
|
40.7 M | - | - | $ 59.7 M | USA |
 |
GlaxoSmithKline plc
GSK
|
216 B | $ 50.28 | -0.27 % | $ 204 B |  Britain |
 |
Sierra Oncology
SRRA
|
288 M | - | -0.05 % | $ 1.34 B |  Canada |
 |
Cocrystal Pharma
COCP
|
11.4 M | $ 1.03 | 2.95 % | $ 11.6 M | USA |
 |
Atea Pharmaceuticals
AVIR
|
426 M | $ 4.27 | 1.18 % | $ 348 M | USA |
 |
Vaccinex
VCNX
|
2.96 M | - | -61.37 % | $ 654 K | USA |
 |
ImmuCell Corporation
ICCC
|
58 M | $ 9.9 | -0.5 % | $ 89.4 M | USA |
 |
Nymox Pharmaceutical Corporation
NYMX
|
18.7 M | - | -19.68 % | $ 18.4 M | Canada |
 |
Akero Therapeutics
AKRO
|
3.25 B | - | - | $ 3.67 B | USA |
 |
Jounce Therapeutics
JNCE
|
47.5 M | - | - | $ 98.4 M | USA |
 |
Immutep Limited
IMMP
|
2.97 B | $ 3.25 | 20.82 % | $ 4.73 B |  Australia |